Analysts’ Recent Ratings Updates for Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (NYSE: BMY) has recently received a number of price target changes and ratings updates:

  • 2/8/2018 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $60.72 price target on the stock.
  • 2/6/2018 – Bristol-Myers Squibb had its price target lowered by analysts at BMO Capital Markets from $52.00 to $51.00. They now have an “underperform” rating on the stock.
  • 2/6/2018 – Bristol-Myers Squibb had its price target raised by analysts at Leerink Swann from $71.00 to $76.00. They now have a “positive” rating on the stock.
  • 2/1/2018 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $60.72 price target on the stock.
  • 1/29/2018 – Bristol-Myers Squibb was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last three months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters.”
  • 1/22/2018 – Bristol-Myers Squibb was given a new $62.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 1/22/2018 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $60.72 price target on the stock.
  • 1/22/2018 – Bristol-Myers Squibb had its “sell” rating reaffirmed by analysts at BMO Capital Markets. They now have a $52.00 price target on the stock.
  • 1/19/2018 – Bristol-Myers Squibb was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last twelve months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters.”
  • 1/16/2018 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $60.72 price target on the stock.
  • 1/9/2018 – Bristol-Myers Squibb was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last twelve months.”
  • 12/28/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $59.70 price target on the stock.
  • 12/22/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $59.70 price target on the stock.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) traded up $0.49 during mid-day trading on Monday, hitting $63.19. The company had a trading volume of 1,778,360 shares, compared to its average volume of 8,534,703. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a twelve month low of $51.56 and a twelve month high of $66.10. The company has a market cap of $103,050.00, a P/E ratio of 107.10, a P/E/G ratio of 1.94 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the company earned $0.63 earnings per share. analysts anticipate that Bristol-Myers Squibb Co will post 3.22 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a $0.40 dividend. The ex-dividend date was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.53%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply